Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Continuous glucose monitoring during late pregnancy and after delivery for gestational diabetes

Official title: Pregnancy and Postpartum Continuous Glucose Monitoring in Gestational Diabetes

Run by Icahn School of Medicine at Mount Sinai · NCT07174245 · Data updated 2026-11-12

This study will collect Dexcom G7 glucose data from people with gestational diabetes during the third trimester and for two weeks after birth to see if those patterns predict an abnormal 6‑week postpartum oral glucose tolerance test.

More Gestational Diabetes trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment40 (estimated)
SponsorIcahn School of Medicine at Mount Sinai
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedAugust 5, 2025
Main results expectedJuly 1, 2027
Study endsJuly 1, 2027
Registry record updatedJuly 8, 2026
Trial IDNCT07174245 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age 18+) with a current diagnosis of gestational diabetes who are prescribed and using a Dexcom G7 are ideal candidates.

Probably not a fit

People with pregestational diabetes, those not using a Dexcom device, those with adhesive allergies preventing CGM use, or those on chronic oral steroids are unlikely to qualify or benefit from this specific protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Pregnant people with a diagnosis of gestational diabetes who are prescribed a Dexcom G7 will continue using their device during the third trimester and wear one sensor for up to 14 days postpartum. Researchers will analyze CGM glucose patterns and compare them to each participant's standard-of-care 6‑week postpartum oral glucose tolerance test result and a remote questionnaire. This is an observational protocol with no experimental treatments, and clinical care remains under the participant's usual providers. The aim is to find glucose pattern predictors of abnormal postpartum glucose tolerance.

Why it matters

Potential benefit: If successful, this approach could help identify patients at higher risk of persistent abnormal blood sugar after pregnancy so follow-up and interventions can be targeted sooner.

How similar studies have gone: CGM has been used in pregnancy to track glucose and guide management, but applying third‑trimester and immediate postpartum CGM data specifically to predict 6‑week OGTT results is a relatively new and only preliminarily studied approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of gestational diabetes during current pregnancy
* age 18 or older
* prescribed Dexcom G7

Exclusion Criteria:

* Pregestational diabetes
* known skin adhesive allergy which inhibits ongoing use of CGM
* chronic oral steroid use.

Where it's running

  • Icahn School of Medicine at Mount Sinai
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Grenye O'Malley, MD — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Sarah Rancic
  • Email: sarah.rancic@mssm.edu
  • Phone: 212-241-5355

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.